Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of nerve growth factor in preparation of medicine for treating sexual debility syndrome of medium-elderly men

A technology of nerve growth factor and sexual function, applied in the field of biomedicine

Active Publication Date: 2014-06-18
BIOPHARM RES & DEV CENT JINAN
View PDF4 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The predecessors have also used cobra venom nerve growth factor to treat male reproductive defects and reduce the effect of gossypol on male spermatogenic function (ZL 00116192.X), but whether nerve growth factor can be used to treat delayed hypogonadism syndrome Not yet reported

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of nerve growth factor in preparation of medicine for treating sexual debility syndrome of medium-elderly men
  • Use of nerve growth factor in preparation of medicine for treating sexual debility syndrome of medium-elderly men
  • Use of nerve growth factor in preparation of medicine for treating sexual debility syndrome of medium-elderly men

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0035] Example 1: Detection of the pro-proliferation effect of rat nerve growth factor on rat Leydig cells

[0036] Materials: Coming 12-well plate (purchased from Corning, USA, product number: 3336), testosterone radioimmunoassay kit (purchased from Beijing North Institute of Biotechnology, product number: B10TFB), human nerve growth factor (purchased from Sigma-Aldrich Shanghai Trading Co., Ltd., product number: N1408-.1MG), rat nerve growth factor (purchased from Sigma-Aldrich Shanghai Trading Co., Ltd., product number: N2513-1MG) or mouse nerve growth factor (purchased from Sigma-Aldrich Shanghai Trading Co., Ltd., product number: SRP4304-20UG), insulin-transferrin-sodium selenite medium supplement (ITS, purchased from Sigma-Aldrich Shanghai Trading Co., Ltd., product number: I1884), luteinizing hormone (LH, Purchased from Sigma-Aldrich Shanghai Trading Co., Ltd., item number: L9773), ethanedimethanylsulfone (EDS, synthesized by the School of Chemical Engineering, Sun Yat-...

Embodiment 2

[0039] Example 2: Detection of the differentiation-promoting effect of rat nerve growth factor on rat testicular mesenchymal stem cells

[0040] Male SPRAGUE-DAWLEY rats (purchased from Guangdong Provincial Medical Animal Experiment Center, 12 weeks old, 250 ± 20 g / rat) were intraperitoneally injected with ethanedimethylsulfone (EDS, 90 mg / kg body weight) 7 days before the experiment, and carbon dioxide After execution, the testes were taken out, placed in ice-cold phosphate buffer, the capsule was cut off, the blood vessels and seminiferous tubules were stripped, and the seminiferous tubules were separated into single ones, and placed in DMEM / F-12 medium (containing 0.1% Bovine serum albumin and 1x insulin-transferrin-sodium selenite medium supplement) were cultured overnight at 34°C and 5% carbon dioxide. The next day, the seminiferous tubules were divided into 24-well plates, and rat nerve growth factor was added for treatment. The concentration of rat nerve growth factor w...

Embodiment 3

[0042] Embodiment 3: Radioimmunoassay analysis of testosterone content in culture medium

[0043]Take 90-day-old SAM R1 mice (3 months old, body weight 26±2g), use forceps to extract the seminiferous tubules in their testes under aseptic condition, wash them with phosphate buffer for 6 times, and then wash them with DMEM / F-12 The culture medium was washed 3 times, and the ethanedimethansulfone (EDS) was added with a final concentration of 375 micrograms / milliliter (ug / ml) to the DMEM / F-12 medium containing 0.1% bovine serum albumin, and the treatment 24 hours. After washing 3 times, change the fresh medium, then place it in an environment of 34°C and 5% carbon dioxide to cultivate, and change it every 3.5 days to contain different concentrations (10, 100 and 200 ng / ml) of human nerve growth factor, Cell culture medium for luteinizing hormone (LH) and platelet-derived growth factor AA (PDGFAA). Finally, the testosterone content in the medium was analyzed by radioimmunoassay. ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to use of a nerve growth factor in preparation of a medicine for treating sexual debility syndrome of medium-elderly men. The nerve growth factor is mainly used for preparing a medicine for treating testosterone content decline of human body caused by decrease of secretion of interstitial cell-stimulating hormone increased by hypophysis or aging of testicular interstitial cells. The nerve growth factor used is originated from humans, mice and rats, preferably humans. The amino acid sequences of the nerve growth factor are shown in SEQ ID No:1-3.

Description

technical field [0001] The invention belongs to the technical field of biomedicine and relates to the second medical application of nerve growth factor. Specifically, the present invention relates to the use of human nerve cell growth factor in the preparation of medicines for treating hypogonadism in middle-aged and elderly males. Nerve cell growth factor derived from humans, rats and mice can be administered through nasal administration or testicular intravenous injection to treat human middle-aged and elderly males with delayed hypogonadism syndrome. Background technique [0002] Late onset hypogonadism in males (LOH) is an age-related hypogonadism in middle-aged and elderly men, and its main features include decreased libido and erection quality (especially nocturnal erection), Emotional changes are accompanied by decreased brain power and spatial orientation, decreased lean body mass (LBM) with decreased muscle volume and strength, decreased body hair and skin changes,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/18A61P15/00A61P15/10
CPCA61K38/18A61K38/185A61K38/1858A61K38/24A61P15/00A61P15/08A61P15/10A61K2300/00
Inventor 黄亚东苏志坚葛仁山陈洁项琪苏泽轩张齐好张磊
Owner BIOPHARM RES & DEV CENT JINAN
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com